

8 January 2024

**ECO Animal Health Group plc**  
("ECO" or the "Company")

**Disposal of Freehold Properties**

ECO Animal Health Group plc (AIM: EAH) announces that on 5 January 2024 the Company completed the sale of its freehold property in New Malden, Surrey. This was the former registered office of the Company and following relocation of all functions to its office in Southgate, London, the office was surplus and unused. The net consideration received for the sale of this property was £831,454. The carrying value of the property was £565,000.

Additionally, on 28 November 2023, the Company's freehold property at Western Road, Mitcham was sold to its long term occupier (an education charity) for net consideration of £227,000. This matched its carrying value and the previous rent payable was a peppercorn.

The total cash received from these two property sales was £1,058,454 after fees and expenses.

The Board intends to use the majority of the net proceeds to advance the growth aspirations of ECO. In due course, the Board also intends to use some of the proceeds to purchase ordinary shares of the Company in the market to cover possible future vesting of employee share-based incentives including share options, long term incentive plans and the deferred bonus scheme. In order to carry out such market purchases, the Company will need to seek approval from shareholders in a general meeting.

For further information please contact:

**ECO Animal Health Group plc** 020 8447 8899  
David Hallas (CEO)  
Christopher Wilks (CFO)

**Singer Capital Markets (Nominated Adviser & Joint Broker)** 020 7496 3000  
Phil Davies  
Sam Butcher

**Investec (Joint Broker)** 020 7597 5970  
Gary Clarence  
Lydia Zychowska

**Equity Developments** 020 7065 2692  
Hannah Crowe  
Matt Evans

**ICR Consilium (Investor Relations)** 020 3709 5700  
Mary-Jane Elliott  
Isabelle Abdou

**About ECO Animal Health**

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DISQKPBBOKDKDK